Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease.

Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study. Osteoporos Int (2012) 4.09

Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol (2009) 3.33

Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol (2008) 2.79

Multivitamin use and risk of cancer and cardiovascular disease in the Women's Health Initiative cohorts. Arch Intern Med (2009) 2.54

Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics (2009) 2.36

Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause (2008) 1.74

Changes in experimental stroke outcome across the life span. J Cereb Blood Flow Metab (2009) 1.58

Middle cerebral artery occlusion model in rodents: methods and potential pitfalls. J Biomed Biotechnol (2011) 1.46

Colorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women's Health Initiative clinical trial and observational study. Cancer Epidemiol Biomarkers Prev (2009) 1.29

Rising adiposity curbing decline in the incidence of myocardial infarction: 20-year follow-up of British men and women in the Whitehall II cohort. Eur Heart J (2011) 1.18

Dietary carbohydrate, glycemic index, and glycemic load in relation to colorectal cancer risk in the Women's Health Initiative. Cancer Causes Control (2008) 1.01

A "window of opportunity:" the reduction of coronary heart disease and total mortality with menopausal therapies is age- and time-dependent. Brain Res (2010) 0.96

Postmenopausal hormone therapy and cardiovascular disease in perspective. Clin Obstet Gynecol (2008) 0.92

The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric (2012) 0.91

Comparing hormone therapy effects in two RCTs and two large observational studies that used similar methods for comprehensive data collection and outcome assessment. BMJ Open (2013) 0.89

Using patient self-reports to study heterogeneity of treatment effects in major depressive disorder. Epidemiol Psychiatr Sci (2016) 0.84

Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke. Semin Reprod Med (2014) 0.82

An analytic framework for aligning observational and randomized trial data: Application to postmenopausal hormone therapy and coronary heart disease. Stat Biosci (2013) 0.82

Transplantation of young ovaries restored cardioprotective influence in postreproductive-aged mice. Aging Cell (2011) 0.82

Trajectories of estradiol and follicle-stimulating hormone over the menopause transition and early markers of atherosclerosis after menopause. Eur J Prev Cardiol (2015) 0.81

Revisiting the timing hypothesis: biomarkers that define the therapeutic window of estrogen for stroke. Horm Behav (2012) 0.81

Data analysis methods and the reliability of analytic epidemiologic research. Epidemiology (2008) 0.78

Women's Health Initiative diet intervention did not increase macular pigment optical density in an ancillary study of a subsample of the Women's Health Initiative. J Nutr (2009) 0.77

Fibroid interventions: reducing symptoms today and tomorrow: extending generalizability by using a comprehensive cohort design with a randomized controlled trial. Am J Obstet Gynecol (2016) 0.77

Embedding clinical interventions into observational studies. Contemp Clin Trials (2015) 0.77

A Dormant Microbial Component in the Development of Preeclampsia. Front Med (Lausanne) (2016) 0.76

Research into Specific Modulators of Vascular Sex Hormone Receptors in the Management of Postmenopausal Cardiovascular Disease. Curr Hypertens Rev (2009) 0.75

Hormone replacement therapy reduces lipid oxidation directly at the arterial wall: A possible link to estrogens' cardioprotective effect through atherosclerosis prevention. J Midlife Health (2017) 0.75

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69

Long-term exposure to air pollution and incidence of cardiovascular events in women. N Engl J Med (2007) 14.90

Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44

Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09

Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA (2003) 11.39

Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61

Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA (2007) 10.50

Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med (2003) 10.06

Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large observational study of the determinants of fracture in older men. Contemp Clin Trials (2005) 9.57

Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73

Estrogen therapy and coronary-artery calcification. N Engl J Med (2007) 8.70

The Women's Health Initiative recruitment methods and results. Ann Epidemiol (2003) 8.42

Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19

Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation (2009) 8.11

Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med (2002) 7.77

National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA (2004) 7.68

Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30

Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA (2013) 7.19

Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12

Diabetes care quality in the Veterans Affairs Health Care System and commercial managed care: the TRIAD study. Ann Intern Med (2004) 6.77

Calcium/vitamin D supplementation and cardiovascular events. Circulation (2007) 6.63

Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51

Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg (2003) 6.50

Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med (2012) 6.46

C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39

Relationship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study. Circulation (2004) 6.15

Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA (2007) 6.02

Dietary sugars intake and cardiovascular health: a scientific statement from the American Heart Association. Circulation (2009) 5.82

Effects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults: a randomized trial. JAMA (2010) 5.77

Low-fat dietary pattern and weight change over 7 years: the Women's Health Initiative Dietary Modification Trial. JAMA (2006) 5.75

FOXO3A genotype is strongly associated with human longevity. Proc Natl Acad Sci U S A (2008) 5.71

Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med (2004) 5.65

Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst (2005) 5.52

Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care (2008) 5.43

Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA (2004) 5.35

Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA (2003) 5.26

Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet (2009) 5.22

Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA (2011) 5.21

14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet (2011) 5.21

Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14

A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89

Effects of estrogen plus progestin on health-related quality of life. N Engl J Med (2003) 4.83

Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med (2009) 4.80

Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol (2005) 4.55

Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA (2008) 4.42

Use of recovery biomarkers to calibrate nutrient consumption self-reports in the Women's Health Initiative. Am J Epidemiol (2008) 4.28

Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study. Arch Intern Med (2005) 4.24

Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension (2007) 4.20

Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07